MPM Oncology Impact Management »

Ventyx Biosciences shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Ventyx Biosciences (VTYX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Ventyx Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Ventyx Biosciences held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ventyx Biosciences by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $15M 1.6M 9.03
2023-06-30 $1.0M 32k 32.80

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Ventyx Biosciences

Affinity Asset Advisors
Vanguard Group
Tang Capital Management
Vestal Point Capital
Citadel Advisors
Braidwell
Susquehanna International
Millennium Management
MPM Oncology Impact Management
Jane Street
Goldman Sachs Group
Connor, Clark & Lunn Investment Management
BlackRock
Redmile Group
Point72 Asset Management

View all funds holding Ventyx Biosciences